Economic Analysis of Domestic and Imported Human Erythropoietin in the Treatment of Elderly Patients with Anemia
OBJECTIVE To provide reference for selecting drug treatment plans in clinical practice,the eco-nomic benefits of domestic and imported human erythropoietin in the treatment of elderly patients with anemia were compared.METHODS 38 cases in each group of elderly patients with anemia who were treated with domestic and imported human erythropoietin injections in a hospital from January 2019 to May 2024 were retrospectively re-viewed.Minimum cost analysis of the two schemes in the treatment of anemia patients was conducted using the data after matching propensity scores.RESULTS The number of cases in the 2 groups was 37 and 33 after matching,re-spectively.Showing no significant differences in gender,age,pre-medication hemoglobin levels,or disease type be-tween the two groups after matching.The total effective rate was calculated with HGB rising≥10 g·L-1,and the ef-fective rate was 51.51％and 48.65％(P＞0.05),respectively.The total cost of domestic and imported human erythropoietin in treating anemia was(389.29±77.62)yuan and(1884.29±554.05)yuan,respectively(P＜0.01).The linear regression results showed that the model was well constructed,and there was no significant influ-ence on the effect of each factor.CONCLUSION Compared with imported human erythropoietin,domestic human erythropoietin had no statistical significance in the clinical efficacy and safety for elderly patients hospitalized with a-nemia for about one month.However,it offered better benefits in short-term economic.
Human erythropoietinDomesticImportedCost-effectiveness analysisPropensity score matching
万方数据
维普
